PMCF Study on CranioFix®2 System Used for the Fixation of Craniotomized Bone Flaps and Fractures (CRANFLAP)
Prospective, Single Center PMCF-study on the Performance and Safety of the CranioFix®2 System Used for the Fixation of Craniotomized Bone Flaps and Fractures to the Neurocranium
Study Overview
Status
Status
Conditions
Conditions
Study Type
Study Type
Enrollment (Actual)
Enrollment
Contacts and Locations
Study Contact
Study Contact
- Name: Franziska Greifzu, Dr.
- Phone Number: +49-7461-95-
- Email: franziska.greifzu@aesculap.de
Study Locations
-
-
-
Stuttgart, Germany, 70174
- Klinikum Stuttgart - Katharinenhospital
-
-
Participation Criteria
Eligibility Criteria
Eligibility Criteria
Ages Eligible for Study
Accepts Healthy Volunteers
Sampling Method
Study Population
Description
Inclusion Criteria:
- Written informed consent
- Age ≥ 18 years
- Use of CranioFix®2 system according to IfU
- Planned postoperative MRI within clinical routine
Exclusion Criteria:
- Pregnancy
- Patients with hypersensitivity to metals or allergies to the implant materials
- Inflammations in the region of the implant site
- Bone conditions that rule out the application of CranioFix®2 titanium clamps
- Use with artificial cranial bone flaps
- Bone tumors in the area supporting the implant
- Degenerative bone diseases
- Missing dura mater
- Application in the facial skull (viscerocranium) and in the orbital or skull-base region
- Combination of implant components from different manufacturers, i.e. additional use of plates and screws on the same bone fragment
Study Plan
How is the study designed?
Design Details
- Observational Models: Cohort
- Time Perspectives: Prospective
What is the study measuring?
Primary Outcome Measures
Primary Outcome Measures
Outcome Measure |
Measure Description |
Time Frame |
|---|---|---|
|
Planarity of Bone Flap After Implantation
Time Frame: Through postoperative course: at discharge (about up to 2 weeks after surgery) and post-operative follow-up (3±2 months after surgery)
|
The primary variable was the planarity of the bone flap after implantation.
The bone flap planarity was evaluated as the rate of patients in which a dislocation of the bone flap occurred - defined as the height of the tilting (depression / protrusion) greater than the bone width.
|
Through postoperative course: at discharge (about up to 2 weeks after surgery) and post-operative follow-up (3±2 months after surgery)
|
Secondary Outcome Measures
Secondary Outcome Measures
Outcome Measure |
Measure Description |
Time Frame |
|---|---|---|
|
Number of Participants With Adverse Events (Intra- and Postoperative)
Time Frame: through study completion, an average of 3 months
|
Number of adverse events e.g.
foreign body reactions, infections, injury to the dura, injury to the scalp, epiduralhaematoma, wound healing disorders with special focus on (serious) adverse events with (possible) relation to the investigational product
|
through study completion, an average of 3 months
|
|
Overall Handling of Instruments for CranioFix®2 System Implantation Documented on a Likert Scale
Time Frame: intraoperative
|
Assessment of handling, documented on a Likert scale 1 to 5 (1 is the very good, 2 is good, 3 is acceptable, 4 is poor, 5 is very poor)
|
intraoperative
|
|
Stability of the Bone Flap After Fixation
Time Frame: intraoperative, at discharge (about up to 2 weeks after surgery) and post-operative follow-up (3±2 months)
|
Assessment of stability of the bone flap, documented on a Likert scale 1 to 5 (1≙very good, 2≙good, 3≙medium, 4≙poor, 5≙very poor)
|
intraoperative, at discharge (about up to 2 weeks after surgery) and post-operative follow-up (3±2 months)
|
|
Cosmetic Outcome
Time Frame: intraoperative, at discharge (about up to 2 weeks after surgery) and post-operative follow-up (3±2 months)
|
Assessment of cosmetic outcome intraoperatively, at discharge and at post-operative follow-up documented on a 3 point scale (good, fair, bad)
|
intraoperative, at discharge (about up to 2 weeks after surgery) and post-operative follow-up (3±2 months)
|
Collaborators and Investigators
Sponsor
Sponsor
Study record dates
Study Major Dates
Study Start (Actual)
Study Start
Primary Completion (Actual)
Primary Completion
Study Completion (Actual)
Study Completion
Study Registration Dates
First Submitted
First Submitted
First Submitted That Met QC Criteria
First Submitted That Met QC Criteria
First Posted (Actual)
First Posted
Study Record Updates
Last Update Posted (Actual)
Last Update Posted
Last Update Submitted That Met QC Criteria
Last Update Submitted That Met QC Criteria
Last Verified
Last Verified
More Information
Terms related to this study
Additional Relevant MeSH Terms
Other Study ID Numbers
Other Study ID Numbers
- AAG-O-H-2043
Drug and device information, study documents
Studies a U.S. FDA-regulated drug product
Studies a U.S. FDA-regulated device product
This information was retrieved directly from the website clinicaltrials.gov without any changes. If you have any requests to change, remove or update your study details, please contact register@clinicaltrials.gov. As soon as a change is implemented on clinicaltrials.gov, this will be updated automatically on our website as well.